The levels of certain indicators of iron status, namely ferritin and transferrin, are altered in patients with amyotrophic lateral sclerosis (ALS) relative to healthy controls, suggesting a possible link between iron metabolism and ALS, a study has found. The results, “Abnormal Serum Iron-Status Indicator Changes in…
Search results for:
The pivotal Phase 3 clinical trial testing BrainStorm Cell Therapeutic’s cell-based therapy NurOwn in amyotrophic lateral sclerosis (ALS) patients continues with only occasional scheduling changes to treatment due to the COVID-19 pandemic. Patient dosing is expected to be complete by July, the company announced. “BrainStorm made…
The Phase 2 clinical trial investigating Clene Nanomedicine‘s CNM-Au8 as a potentially disease-modifying therapy for people with amyotrophic lateral sclerosis (ALS) has enrolled more than half of its participants ahead of schedule. RESCUE-ALS (NCT04098406) dosed its first participant in January,…
1. Why is this survey being conducted? The purpose of this survey is to gather information from individuals with amyotrophic lateral sclerosis (ALS) so that Bionews and its partners can bring better understanding, advocacy, and provide our readers more relevant editorial content to the larger ALS community. 2. What will…
CONSENT FOR SURVEY PARTICIPATION Why is this survey being conducted? The purpose of this survey is to gather information from individuals with amyotrophic lateral sclerosis (ALS) so that Bionews Services and its partners can bring better understanding, advocacy, and provide our readers more relevant editorial content to the larger ALS…
Seneca Biopharma announced that work is underway to advance NSI-566, its leading stem cell treatment candidate, into a Phase 3 study in people with amyotrophic lateral sclerosis (ALS). The decision followed a meeting with the US Food and Drug Administration (FDA), and is supported by data collected from…
By blocking the activity of the proteasome — a complex of enzymes responsible for the destruction of unnecessary or damaged proteins — dipeptide repeat (DPR) proteins associated with C9ORF72 gene repeat expansions (the most common genetic cause of amyotrophic lateral sclerosis) can travel between nerve cells…
COVID-19, short for coronavirus disease 2019, is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly identified and highly contagious pathogen not previously seen in humans. Though it belongs to the same category of viruses as SARS and influenza…
Bloom Science and Duke University have entered into an exclusive licensing agreement that provides the biopharmaceutical company access to the intellectual property and technology related to unique strain isolates and genetic variants of Akkermansia genus bacteria. This type of bacteria has been demonstrated to slow disease progression…
News
AI-based Platform Suggests Cancer Candidate LAM-002 as Possible ALS Therapy, AI Therapeutics Says
AI Therapeutics‘ lymphoma candidate LAM-002 was identified by the company’s artificial intelligence-based platform — called Guardian Angel — as a possible treatment for amyotrophic lateral sclerosis (ALS). Researchers from AI have already tested and confirmed LAM-002’s therapeutic potential in an ALS context. Now, an independent…